Is continuous infusion of β-lactam antibiotics worthwhile? - Efficacy and pharmacokinetic considerations

Journal of Antimicrobial Chemotherapy

Volumn 38, Issue 1, 1996, Pages 5-15

  Mouton, Johan W ^a   Vinks, Alexander A T M M ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Clinical Pharmacy   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM;

ANIMAL; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGICAL EXAMINATION; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 0030179332     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/38.1.5     Document Type: Review

References (45)

1. Akkerman, S. R., Dix, S. P., Lampasona, V., Mullins, R. E., Wingard, J. R. & Saral, R. (1992). Pharmacokinetics of continuous infusion ceftazidime in febrile neutropenic bone marrow transplant patients. Pharmacotherapy 12, 506.
2. Barza, M. & Cuchural, G. (1985). General principles of antibiotic tissue penetration. Journal of Antimicrobial Chemotherapy 15, Suppl. A, 59-75.
3. Bodey, G. P., Ketchel, S. J. & Rodriguez, V. (1979). A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. American Journal of Medicine 67, 608-16.
4. Byl, B., Baran, D., Herchuelz, A., Roucloux, I., Lambert, C., van der Auwera, A. P. et al. (1992). Sputum penetration of a single daily dose of amikacin and of a continuous infusion of ceftazidime in cystic fibrosis. In Program and Abstracts of the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, 1992. Abstract 209, p. 145. American Society for Microbiology, Washington, DC.
5. Cappelletty, D. M., Kang, L., Palmer, S. M. & Rybak, M. J. (1995). Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model. Antimicrobial Agents and Chemotherapy 39, 1797-801.
6. Castela, N., Taburet, A. M., Carlet, J., Nitenberg, G., Wolff, M., Sollet, J. P. et al. (1994). Pharmacokinetics of ceftazidime during continuous infusion in intensive care patients. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, 1994. Abstract A11, p. 16. American Society for Microbiology, Washington, DC.
7. Craig, W. A. (1993). Qualitative susceptibility tests versus quantitative MIC tests. Diagnostic Microbiology and Infectious Diseases 16, 231-6.
8. Craig, W. A. & Ebert, S. C. (1992). Continuous infusion of beta-lactam antibiotics. Antimicrobial Agents and Chemotherapy 36, 2577-83.
9. Daenen, S. & de Vries-Hospers, H. (1988). Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime. Lancet i, 937.
10. Daenen, S., Erjavec, Z., Uges, D. R. A., De Vries-Hospers, H. G., De Jonge, P. & Halie, M. R. (1995). Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia. European Journal of Microbiology and Infectious Disease 14, 188-92.
11. David, T. J. & Devlin, J. (1989). Continuous infusion of ceftazidime in cystic fibrosis. Lancet i, 1454-5.
12. Drusano, G. L. (1991). Human pharmacodynamics of beta-lactams, aminoglycosides and their combination. Scandinavian Journal Infectious Diseases, Suppl. 74, 235-48.
13. Fluckiger, U., Segessenmann, C. & Gerber, A. U. (1991). Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrobial Agents and Chemotherapy 35, 1905-10.
14. Giacomini, K. M., Roberts, S. M. & Levy, G. (1981). Evaluation of methods for producing renal dysfunction in rats. Journal of Pharmaceutical Sciences 70, 117-21.
15. Hedman, A., Adan-Abdi, Y., Alvan, G., Starndvik, B. & Arvidsson, A. (1988). Influence of the glomerular filtration rate on renal clearance of ceftazidime in cystic fibrosis. Clinical Pharmacokinetics 15, 57-65.
16. Klepser, M. E., Marangos, M. N., Patel, K. B., Nicolau, D. P., Quinitiliani, R. & Nightingale, C. H. (1995). Clinical pharmacokinetics of newer cephalosporins. Clinical Pharmacokinetics 28, 361-84.
17. Knudsen, J. D., Frimodt-Moller, N. & Espersen, F. (1995). Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin. Antimicrobial Agents and Chemotherapy 39, 1253-8.
18. Kunst, M. W. & Mattie, H. (1978). Cefazolin and cephradine: relationship between serum concentrations and tissue contents in mice. Infection 6, 166-70.
19. Kuzemko, J. & Crawford, C. (1989). Continuous infusion of ceftazidime in cystic fibrosis. Lancet ii, 385.
20. Lagast, H., Meunier-Carpentier, F. & Klasterski, J. (1983). Treatment of Gram-negative bacillary septicaemia with cefoperazone. European Journal of Microbiology and Infectious Disease 2, 554-8.
21. Le Normand, Y., Avetloiseau, H., Kergueris, M. F. & Mechinaud, F. (1993). Ceftazidime and vancomycin constant-rate infusion in neutropenic children: pharmacokinetic parameters and clinical implications. In Program and Abstracts of the Thirty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans 1993. Abstract 939, p. 291. American Society for Microbiology, Washington, DC.
22. Mammen, G. J. (1990). Drug Data Handbook. (Mammen G. J., Ed.). Adis, Auckland.
23. Mattie, H., Hoogeterp, J. J. & Hermans, J. (1987). The relation between plasma and tissue concentrations of antibiotics. Description of a method. Journal of Pharmacokinetics and Biopharmacy 15, 191-202.
24. Merrikin, D. J., Briant, J. & Rolinson, G. N. (1983). Effect of proteinbinding on antibiotic activity in vivo. Journal of Antimicrobial Chemotherapy 11, 233-8.
25. Mouton, J. W. & den Hollander, J. G. (1994). Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrobial Agents and Chemotherapy 38, 931-6.
26. Mouton, J. W., Horrevorts, A. M., Mulder, P. G. H., Prens, E. P. & Michel, M. F. (1990). Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous infusion and intermittent infusions in healthy volunteers. Antimicrobial Agents and Chemotherapy 34, 2307-11.
27. Mouton, J. W., Horrevorts, A. M., Overbeek, S. E., Kerrebijn, K. F. & Michel, M. F. (1992). Pharmacokinetics of ceftazidime during continuous and intermittent infusion in adult cystic fibrosis patients. In Program and Abstracts of the XIth International Cystic Fibrosis Congress, Dublin, 1992. Abstract TP16. Cystic Fibrosis Association, Dublin.
28. Mouton, J. W. & Michel, M. F. (1991). Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion. Journal of Antimicrobial Chemotherapy 28, 911-8.
29. Mouton, J. W. & van den Anker, J. N. (1995). Meropenem clinical pharmacokinetics. Clinical Pharmacokinetics 28, 275-86.
30. Nicolau, D. P., Nightingale, C. H., Banevicus, M. A., Fu, Q. & Quintiliani, R. (1994). Ceftazidime serum bactericidal activity: continuous infusion versus intermittent injections. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando 1994. Abstract A90, p. 118. American Society for Microbiology, Washington, DC.
31. Onyeji, C. O., Nicolau, D. P., Nightingale, C. H. & Quintiliani, R. (1994). Optimal times above MICs of ceftibuten and cefactor in experimental intra-abdominal infections. Antimicrobial Agents and Chemotherapy 38, 1112-7.
32. Rio, Y., Leroy, F., Humbert, G., Didion, J. & Jurin, F. (1994). Comparative ceftazidime serum concentrations during continuous infusion in healthy subjects and severe burn patients. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, 1994. Abstract A13, p. 16. American Society for Microbiology, Washington, DC.
33. Roosendaal, R., Bakker-Woudenberg, I. A., van den Berg, J. C. & Michel, M. F. (1985). Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats. Journal of Infectious Diseases 152, 373-8.
34. Roosendaal, R., Bakker-Woudenberg, I. A., van den Berghe-van Raffe, M. & Michel, M. F. (1986). Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats. Antimicrobial Agents and Chemotherapy 30, 403-8.
35. Schentag, J. J., Smith, I. L., Swanson, D. J., DeAngelis, C., Fracasso, J. E., Vari, A. et al. (1984). Role for dual individualization with cefmenoxime. American Journal of Medicine 77, 43-50.
36. Smith, H., Dewdney, J. M. & Wheeler, A. W. (1971). A comparison of the amounts and the antigenecity of polymeric materials formed in aqueous solutions by some beta-lactam antibiotics. Immunology 21, 527-33.
37. Spino, M. (1991). Pharmacokinetics of drugs in cystic fibrosis. Clinical Reviews of Allergy 9, 169-210.
38. Vinks, A. A. T. M. M., Mouton, J. W., Touw, D. J., Heijerman, H. G. M., Danhof, M. & Bakker, W. (1995a). Population pharmacokinetics of ceftazidime in cystic fibrosis patients analyzed by using a non-parametric algorithm and optimal sampling strategy. Antimicrobial Agents and Chemotherapy 40, 1091-7.
39. Vinks, A. A. T. M. M., Rossem, R. N., van Touw, D. J., Heijerman, H. G. M., Danhof, M. & Bakker, W. (1995b). Aztreonam pharmacokinetics after single dose and during home treatment in cystic fibrosis patients. Pharmacy World and Science 17, Suppl. D5. Abstract.
40. Vinks, A. A. T. M. M., Touw, D. J., Heijerman, H. G. M., Danhof, M., de Leede, G. P. J. & Bakker, W. (1994). Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Therapeutic Drug Monitoring 16, 341-8.
41. Visser, L. G., Arnouts, P., van Furth, R., Mattie, H. & van den Broek, P. J. (1993). Clinical pharmacokinetics of continuous administration of penicillins. Clinical Infectious Diseases 17, 491-5.
42. Vogelman, B. & Craig, W. A. (1986). Kinetics of antimicrobial activity. Journal of Pediatrics 108, 835-40.
43. Wise, R. (1983). Protein binding of beta-lactams: the effects on activity and pharmacology particularly tissue penetration. I. Journal of Antimicrobial Chemotherapy 12, 1-18.
44. Wise, R. (1986). Methods for evaluating the penetration of beta-lactams into tissues. Reviews of Infectious Diseases 8, Suppl. 3, 325-32.
45. Xiong, Y. Q., Potel, G., Caillon, J., Bugnon, D., Le Conte, P. H., Baron, D. et al. (1994). Determination of the in vivo efficaceous serum concentrations of ceftazidime administered as continuous infusion on an experimental model of Pseudomonas aeruginosa rabbit endocarditis model. In Program and Abstracts of the Thirty-Fourth Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando, 1994. Abstract A88, p. 118. American Society for Microbiology, Washington, DC.